pISSN 2234-3806eISSN 2234-3814
Table. 2.
Results of cost-effectiveness analysis
| Testing strategy | Cost ($) | PF-LYG (y) | ICER ($/PF-LYG) |
|---|---|---|---|
| Strategy 1 | 1,680.0 | 0.41 | 3,978.4 |
| Strategy 2 | 1,711.1 | 0.41 | 4,054.1 |
| Strategy 3 | 1,773.5 | 0.41 | 4,205.7 |
| Strategy 4 | 784.9 | 0.29 | 2,547.7 |
| Strategy 5 | 1,696.9 | 0.41 | 4,019.7 |
| No testing (comparator) | 42.3 | referent | – |
Abbreviations: PF-LYG, progression-free life-year gain; ICER, incremental cost-effectiveness ratio.
Ann Lab Med 2023;43:73~81 https://doi.org/10.3343/alm.2023.43.1.73
© Ann Lab Med